Showing 3741-3750 of 4164 results for "".
- Ocuphire Publishes Phase 3 Trial Results of Ryzumvi for Reversal of Pharmacologically-Induced Mydriasishttps://modernod.com/news/ocuphire-publishes-phase-3-trial-results-of-ryzumvi-for-pharmacologically-induced-mydriasis-1/2482463/Ocuphire Pharma announced the full results from two pivotal phase 3 clinical trials (MIRA-2 and MIRA-3) that evaluated the safety and efficacy of Ryzumvi (phentolamine ophthalmic solution 0.75%) for reversing pharmacologically-induced mydriasis. The data were
- Alkeus Pharmaceuticals Announces Positive Results from SAGA Study of Gildeuretinol Acetate in GA Patientshttps://modernod.com/news/alkeus-pharmaceuticals-announces-positive-results-from-saga-study-of-gildeuretinol-acetate-in-ga-patients-3/2482445/Alkeus Pharmaceuticals announced results from the SAGA study, a phase 3 clinical trial of oral gildeuretinol acetate (ALK-001) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The study demonstrated a reduction in the growth rate of GA lesions by
- Viridian Announces Positive Topline Results from Phase 3 Trial of Veligrotug for TEDhttps://modernod.com/news/viridian-announces-positive-topline-results-from-phase-3-trial-of-veligrotug-for-thyroid-eye-disease/2482434/Viridian Therapeutics announced positive topline data from its THRIVE phase 3 clinical trial of VRDN-001, now branded as veligrotug, in patients with active thyroid eye disease (TED). Veligrotug, an intravenously administered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, demo
- Ocuphire Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopiahttps://modernod.com/news/ocuphire-initiates-vega-3-phase-3-trial-evaluating-phentolamine-ophthalmic-solution-075-for-presbyopia/2482432/Ocuphire Pharma announced the first dosing of participants in its VEGA-3 phase 3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia. Ocuphire’s phentolamine ophthalmic solution 0.75% is being developed as a potential alternative t
- Aurion Biotech to Present at ESCRS and Ophthalmology Futures European Forumhttps://modernod.com/news/aurion-biotech-to-present-at-escrs-and-ophthalmology-futures-european-forum/2482430/Aurion Biotech announced its upcoming participation in the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), September 6-10, 2024, in Barcelona. The company will showcase clinical data on its allogeneic cell therapy drug candidate, AURN001. Aurion w
- Opthea Announces Executive Leadership Changes and Senior Hireshttps://modernod.com/news/opthea-announces-executive-leadership-changes-and-senior-hires/2482429/Opthea announced several executive leadership changes aimed at bolstering the company’s commercial and clinical expertise as it prepares for the anticipated 2025 topline data readout of phase 3 trials for its lead candidate, sozinibercept, in wet AMD. Daniel Geffken, Co-Founder an
- Ciliatech to Present 36-Month Follow-Up Results on Intercil Uveal Spacer at Ophthalmology Futures European Forumhttps://modernod.com/news/ciliatech-to-present-36-month-follow-up-results-on-intercil-uveal-spacer-at-ophthalmology-futures-european-forum/2482427/Ciliatech has announced that it will reveal the combined 36-month follow-up results of its SAFARI I & II clinical trials at the Ophthalmology Futures European Forum on September 5. The company will share data on its Intercil Uveal Spacer, a Cilioscleral Interpositioning Device (CID) designed
- ViaLase to Present Glaucoma Treatment Data at ESCRS 2024 in Barcelonahttps://modernod.com/news/vialase-to-present-glaucoma-treatment-data-at-escrs-2024-in-barcelona/2482423/ViaLase will present clinical data and provide an overview of its business and technology during the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), September 6-10, 2024, in Barcelona, Spain. ViaLase will be exhibiting at the Teleon Surgical booth (Boo
- LumiThera Announces First CPT Code to Report Photobiomodulation Therapy in Retinal Diseasehttps://modernod.com/news/lumithera-announces-first-cpt-code-to-report-photobiomodulation-therapy-in-retinal-disease/2482389/LumiThera announced a new Category III CPT code, effective January 1, 2025. The code, "Photobiomodulation therapy of retina, single session,” was approved by the AMA’s CPT Editorial Panel at the May 2024 meeting.[1] The LIGHTSITE III clinical trial was a
- FDA Notifies Ocular Therapeutix that SOL-R Trial is Appropriate as a Registrational Study in Wet AMDhttps://modernod.com/news/fda-notifies-ocular-therapeutix-that-sol-r-trial-is-appropriate-as-a-registrational-study-in-wet-amd/2482388/Ocular Therapeutix announced that it has received a written response from the FDA that the phase 3 SOL-R clinical trial is appropriate for use as the company’s second adequate and well controlled study of Axpaxli (axitinib intravitreal implant, also known as OTX-TKI) for the